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INTRODUCTION
Mucormycosis (formerly known as zygomycosis) and aspergil-
losis are invasive fungal diseases that usually present as rhino-
orbital-cerebral or pulmonary infections.1,2 Aspergillus species 
are usually susceptible to voriconazole, and isavuconazole has 
also become a first-line targeted therapy.3 However, voricon-
azole shows no activity against mucorales.3 Moreover, con-
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accord with a histopathological diagnosis of aspergillosis or mucormycosis; 15 samples had discordant histopathology and PCR 
results. No azole-mediating cyp51A gene mutation was noted among nine cases of aspergillosis. Moreover, no cyp51A mutations 
were identified among three cases with history of prior azole use. 
Conclusion: Panfungal PCR assay with FFPE samples may provide additional information of use to fungal species identification. No 
azole-resistance mediating mutations in the A. fumigatus cyp51A gene were identified among FFPE samples during study period. 
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cerns about changing epidemiology and azole resistance are 
rising. A study using a deterministic model estimated the an-
nual incidence of invasive aspergillosis (IA) and mucormyco-
sis in South Korea to be 4.48 and 0.14 cases/100,000 people, re-
spectively. A retrospective study performed in 10 university 
hospitals identified 334 cases of invasive pulmonary aspergil-
losis between 2008 and 2010. Another study collected 102 clin-
ical and 129 environmental Aspergillus isolates from patients 
with hematologic malignancies in South Korea and evaluated 
the prevalence of azole resistance. In the study, the resistance 
rate of A. fumigatus to azole was 5.3%.4-6
Higher rates of mortality have been demonstrated for pa-
tients treated with voriconazole in voriconazole-resistant IA 
than for voriconazole-susceptible IA.7,8 Rapid detection of 
fungal species and of azole-resistance in Aspergillosis fumiga-
tus may benefit outcomes by guiding appropriate antifungal 
therapy.7
Azoles are inhibitors of 14α-sterol demethylases, which are re-
sponsible for catalyzing a critical step in the biosynthesis of er-
gosterol, a component of the fungal membrane.8 Mutations in 
the cyp51A gene, which is responsible for encoding 14α-sterol 
demethylase enzymes, is the most common azole-resistance 
mechanism in Aspergillus species.9 Moreover, isolates harboring 
tandem repeats in the promoter region of the cyp51A gene and 
point mutations leading to amino acid changes are also known 
to cause azole-resistance.9 Furthermore, the incidence of azole-
resistant Aspergillus species has increased over recent years due 
to previous exposure and environment-associated resistance.8,10 
Molecular methods can now be used to rapidly identify 
fungal species in formalin-fixed paraffin-embedded (FFPE) 
tissue specimens,11 and polymerase chain reaction (PCR)-
based methods have been devised to detect azole-resistance 
in FFPE and bronchial alveolar lavage specimens.12,13 The ob-
jectives of this study were to evaluate performance of panfun-
gal PCR assays on FFPE samples for fungal species identifica-
tion, and the detection of azole-resistance mutations in the A. 
fumigatus cyp51A gene at a South Korean hospital.
MATERIALS AND METHODS
Clinical samples and DNA extraction
Histopathology reports consistent with aspergillosis or mu-
cormycosis issued between January 2006 and January 2016 
and relevant FFPE blocks were retrieved from the Department 
of Pathology at a tertiary referral hospital in South Korea. Eth-
ics approval was obtained from the hospital’s Institutional Re-
view Board (Yonsei University Health System, Severance Hos-
pital, IRB trial number: 4-2016-0262). Panfungal PCR assays 
were performed on these FFPE blocks to determine the pres-
ence of Aspergillus species and Mucorales. Samples testing 
positive for A. fumigatus by DNA sequencing were subjected 
to L98H, M220, and TR46 PCR assays and consecutive DNA 
sequence analysis to determine the presence of azole-resis-
tance mutations in the A. fumigatus cyp51A gene.
FFPE tissues were deparaffinized with mineral oil, and DNA 
was extracted with proteinase K using the ReliaPrepTM FFPE 
gDNA Miniprep System (Promega, Madison, WI, USA), ac-
cording to the manufacturer’s instructions. DNA isolation 
with deparaffinization using mineral oil was performed using 
the ReliaPrepTM FFPE gDNA Miniprep System. 500 μL of min-
eral oil was added to the sections. Sample lysis was done by 
adding 200 μL of lysis buffer to the sample, followed by cen-
trifugation of 10000 rpm for 15 seconds. Then, 20 μL of Pro-
teinase K was added to the lower phase and incubated at 56°C 
and 80°C for 1 and 4 hours, each. 10 μL of RNase A was added 
directly to the lysed sample in the lower phase and incubated 
at room temperature (20–25°C) for 5 minutes. Next, 220 μL of 
BL Buffer and 240 μL of ethanol (95–100%) were added to the 
lysed sample. After centrifugation at 10000 rpm for 15 sec-
onds, the entire lower blue (aqueous) phase of the sample 
was transferred to a binding column/collection tube assem-
bly. After transfer, centrifugation at 10000 rpm for 30 seconds 
was done. Next, 500 μL of 1X wash solution was added to the 
binding column and centrifuged at 10000 rpm for 30 seconds. 
The flow-through was discarded, and 500 μL of 1X wash solu-
tion was added to the binding column, followed by centrifu-
gation at 10000×g for 30 seconds. The flow-through was once 
again discarded, followed by centrifugation at 16000×g for 3 
minutes to dry the column. The binding column was trans-
ferred to a clean 1.5-mL microcentrifuge tube, to which 30–50 
μL of elution buffer was added. After centrifugation at 16000 
×g for 1 minute, the extracted DNA was stored at -20°C. Final-
ly, agarose gel electrophoresis and PCR methods were used to 
assess DNA degradation.
Primers for PCR assays of Aspergillus species and 
Mucormycosis identification
Panfungal PCR was performed to amplify internal transcribed 
spacer (ITS) regions. The primers ITS5 (forward; 5’GGAAGTA-
AAAGTCGTAACG-3’) and ITS4 (reverse; 5’-TCCTCCGCTTATT-
GATATGC-3’) were used to amplify ITS 1 to ITS 2 regions (ITS 
1–2), and the primers ITS3 (forward; 5’-GCATCGATGAAGAAC-
GCAGC-3’) and ITS4 (reverse; 5’-TCCTCCGCTTATTGATAT-
GC-3’) were used to amplify the ITS 2 region.14 The ITS 1–2 and 
ITS 2 PCR products obtained were of 640 and 350 base pairs 
(bp), respectively (Supplementary Table 1, only online).
Primers for PCR assays of cyp51A gene mutations
To amplify L98H, M220, and TR46 mutations in the cyp51A 
gene, we used a previously described nested, one-step PCR 
assay.15 Three different primer sets were used to amplify these 
three mutations. To amplify L98H, we used 5’-AAAAAACCA-
CAGTCTACCTGG-3’ (forward), and 5’-GGAATTGGGACAAT-
CATACAC-3’ (reverse) to generate a 143-bp PCR fragment.16 
For M220, we used 5’-GCCAGGAAGTTCGTTCCAA-3’ (for-
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ward) and 5’-CTGATTGATGATGTCAACGTA-3’ (reverse) to 
generate a 173-bp PCR fragment.16 Nested PCR assay was per-
formed to amplify TR46 in the promoter region of cyp51A: one 
primer pair was used to amplify a long DNA fragment, and a 
second primer pair was used to amplify an inner shorter frag-
ment in a second PCR step. For the first step, the PCR primer 
pairs were 5’-AAGCACTCTGAATAATTTACA-3’ (forward) and 
5’-ACCAATATAGGTTCATAGGT-3’ (reverse) to obtain a 240-
bp DNA fragment, and in the second step, 5’-GAGTGAATA-
ATCGCAGCACC-3’ (forward) and 5’-CTGGAACTACACCT-
TAGTAATT-3’ (reverse) were used to generate a 103-bp DNA 
fragment (Supplementary Table 2, only online).15
PCR assays and controls
To amplify ITS regions, PCR was performed in total volumes 
of 50 μL, consisting of 1X reaction buffer, 0.1 μM dNTPmix, 
1.25 U of Taq DNA Polymerase (RBC Bioscience, Xindian City, 
Taiwan), 20 pmoL of each primer, and 200 ng of DNA (1 μL) 
per sample. PCR was performed using the following protocol: 
95°C for 3 minutes, 35 amplification cycles of 94°C for 30 sec-
onds, 50°C for 1 minute, and 72°C for 1 minute, and a final ex-
tension at 72°C for 7 minutes.
To detect L98H and M220 alterations, PCR was conducted in 
a total volume of 50 μL containing 2 μL of template DNA (100 
ng human DNA+unknown amount of A. fumigatus DNA), 1X 
reaction buffer, 0.1 μM dNTPmix, 1.25 U of Taq DNA Poly-
merase (RBC Bioscience), and 20 pmoL of each primer. The 
PCR amplification protocol was as follows: 5 min of initial de-
naturation at 94°C, 39 amplification cycles of 94°C for 45 s, 
52°C for 1 min, and 72°C for 1 min, and final extension at 72°C 
for 10 min. 
To detect TR46 alterations, PCR was conducted in a total 
volume of 50 µL as described for L98H and M220 above. The 
PCR amplification protocol was as follows: 5 min denatur-
ation at 94°C, 22 amplification cycles of 94°C for 45 s, 52°C for 
1 min, and 72°C for 1 min, and final extension at 72°C for 5 
min. For the second PCR step, we used a total volume of 50 μL 
and 3 μL of the first-step PCR mixture as template. Other com-
ponents were as described for L98H and M220. The second 
step PCR amplification protocol was as follows: 5 min initial 
denaturation at 94°C, 34 amplification cycles of 94°C for 45 s, 
56°C for 1 min, and 72°C for 1 min, and final extension at 72°C 
for 5 min. 
To exclude cross-reactivity of the primers with human ge-
nomic DNA, samples containing a mixture of 100 ng of hu-
man DNA and 50 pg of A. fumigatus wild-type DNA were used 
as a negative control. An azole-resistant A. fumigatus strain 
(GenBank accession no. AF338659) harboring the TR34/
L98H/S297T/F495L mutation in the cyp51A gene was used as 
a positive control for detection of the L98H mutation.17 
Sequence analysis
To identify Aspergillus species and Mucorales, PCR products 
were purified using the MinElute PCR Purification Kit (Qiagen, 
Hilden, Germany). A minimum of 50 ng DNA was sequenced 
using the BigDye Terminator Cycle Sequencing Kit, version 3.1 
(Applied Biosystems, Foster City, CA, USA) and an Applied Bio-
systems 3730XL DNA Analyzer (Applied Biosystems). Sequenc-
es were edited and aligned using Sequence Scanner Software 2, 
ver. 2.0 (Applied Biosystems), and product sequences were 
compared with reference sequences using the NCBI alignment 
service Nucleotide BLAST (https://blast.ncbi.nlm.nih.gov/
Blast.cgi). The GenBank accession number for the A. fumigatus 
sequences determined in this study is CM000169.1.
To detect potential mutations in the PCR products subject-
ed to DNA sequence analysis, sequences were compared with 
the A. fumigatus cyp51A wild-type sequence using the NCBI 
alignment service Nucleotide BLAST (https://blast.ncbi.nlm.
nih.gov/Blast.cgi).
RESULTS
During the 10-year study period, 75 patients received a histo-
pathological diagnosis of mucormycosis or aspergillosis, and 
PCR amplification and identification was positive for 31 
(41.3%) of the 75 FFPE samples. Sixteen FFPE samples had 
corresponding histopathology and PCR sequencing results. 
Fourteen cases of Aspergillus species were identified: A. fu-
migatus (n=9), A. flavus (n=2), A. oryzae (n=2), and A. tamarii 
(n=1). Two cases with a histopathological diagnosis of mucor-
mycosis were identified as Rhizopus oryzae by sequence 
analysis. The nine cases identified as A. fumigatus species 
were further analyzed for azole-resistance mutations in the A. 
fumigatus cyp51A gene. 
The demographic and clinical data of the 16 cases identified 
as aspergillosis or mucormycosis by panfungal PCR are pre-
sented in Table 1. Case 1, a 77-year-old male, had a history of 
chronic obstructive pulmonary disease and was receiving ste-
roids when he developed a brain abscess. An empirical anti-
bacterial agent, but no antifungal agent, was administered. As-
pergillosis was confirmed after death by pathologic diagnosis, 
and PCR sequencing confirmed A. fumigatus. Case 2 was an 
81-year-old male patient who developed fungal pneumonia 
after surgery for renal cell carcinoma. Pathologic diagnosis 
conducted on transbronchial lung biopsy tissue revealed as-
pergillosis. The patient was treated with voriconazole but suc-
cumbed despite appropriate treatment. PCR sequencing iden-
tified A. fumigatus. Case 4 was a 75-year-old male patient who 
had undergone liver transplantation due to hepatocellular car-
cinoma and was receiving immunosuppressive therapy and 
oral itraconazole for fungal prophylaxis prior to developing 
acute maxillary sinusitis. Case 5 was a 62-year-old female and 
had undergone liver transplantation due to liver cirrhosis. A 
mass lesion developed in her chest wall area at 1 year after 
transplantation. Excisional biopsy revealed narrow branching 
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fungal hyphae consistent with aspergillosis, and PCR sequenc-
ing demonstrated the presence of A. fumigatus. The patient 
was receiving fluconazole for fungal prophylaxis. Treatment, 
which involved excision and systemic voriconazole, was suc-
cessful in this case. Case 9 was a 54-year-old male who had un-
dergone a lung transplant due to idiopathic pulmonary fibro-
sis. He had a history of itraconazole use for fungal prophylaxis. 
Case 15 was a 62-year-old male who had undergone kidney 
transplantation due to diabetic nephropathy. Histopathologic 
diagnosis after stomach biopsy revealed mucormycosis. De-
spite treatment with liposomal amphotericin B, the patient ex-
pired. PCR sequencing results identified R. oryzae. Case 16 
was a 69-year-old male with diabetes mellitus on insulin ther-
apy when he developed maxillary sinusitis. Mucormycosis was 
confirmed by histopathology and was consistent with PCR re-
sults, which demonstrated R. oryzae.
The results of the cyp51A alterations of the nine samples 
confirmed as A. fumigatus are summarized in Table 1. Seven 
samples were positive by the L98H PCR assay alone, but no 
mutations were detected in sequence analysis. Seven samples 
were positive by the M220 PCR assay alone, but also revealed 
no mutations in sequence analysis. Six samples were positive 
by the TR 46 PCR assay alone, but similarly, no mutations 
were noted in sequence analysis. 
Discordant PCR and histopathology results were obtained 
for 15 samples. Two specimens histopathologically diagnosed 
as Aspergillosis were identified as Mucorales: Lichtheimia ra-
mosa and R. oryzae. Five specimens with a histopathological 
diagnosis of aspergillosis were identified by PCR as Epicoccum 
nigrum, Bipolaris zeicola, Fusarium solani, Nakataea oryzae, 
and Cladosporium cladosporioides. Eight samples were iden-
tified by PCR sequencing as uncultured fungus clones. One 
brain sample diagnosed as mucormycosis by histopathology 
was identified by PCR as an uncultured fungus clone. L. ra-
mosa was identified by PCR in buttock tissue. R. oryzae, B. ze-
icola, F. solani, and N. oryzae were all identified in sinus sam-
ples with uncultured fungus clones, and E. nigrum and C. 
cladosporioides were identified in lung samples. 
DISCUSSION
The identification of fungal DNA in tissue samples by PCR im-
proves diagnostic accuracies for fungal infections,3 and pan-
fungal PCR conducted on FFPE tissues provides an alternative 
to culture-dependent identification methods.11 Mucorales has 
been identified by PCR in paraffin-embedded tissue samples 
of patients with a fungal infection,14,18 and studies have shown 
that fungal organisms can be identified by amplifying fungal 
ITS 1 and 2 using panfungal primers.14 The results of the pres-
ent study support research indicating that PCR amplification 
of the ITS 1 and 2 regions accurately diagnoses fungal species 






















1 M/77 COPD Brain Aspergillosis A. fumigatus NG Neg No Yes Neg Neg NT
2 M/81 Renal cell carcinoma Lung Aspergillosis A. fumigatus NG Neg No Yes Neg Neg Neg
3 M/62 Chronic sinusitis Maxillary sinus Aspergillosis A. fumigatus NT NT No No Neg NT NT
4 M/75 Liver transplantation* Maxillary sinus Aspergillosis A. fumigatus NT Neg Yes No Neg Neg NT
5 F/62 Liver transplantation* Soft tissue/bone§ Aspergillosis A. fumigatus NG Pos Yes No Neg Neg Neg
6 F/74 Chronic sinusitis Maxillary sinus Aspergillosis A. fumigatus NT NT No No NT NT Neg
7 F/78 ESRD Maxillary sinus Aspergillosis A. fumigatus NT NT No No NT Neg Neg
8 F/58 Chronic sinusitis Maxillary sinus Aspergillosis A. fumigatus NT NT No No Neg Neg Neg
9 M/54 Lung transplantation† Lung Aspergillosis A. fumigatus NG Pos Yes No Neg Neg Neg
10 M/73 Diabetes mellitus Maxillary sinus Aspergillosis A. flavus NT NT No No
11 M/71 Cervix cancer, CKD Lung Aspergillosis A. tamarii Fungus Pos Yes Yes
12 M/52 Chronic sinusitis Maxillary sinus Aspergillosis A. oryzae NT NT No No
13 F/62 Chronic sinusitis Maxillary sinus Aspergillosis A. oryzae NT NT No No
14 M/65 ESRD Maxillary sinus Aspergillosis A. flavus NT NT No No
15 M/62 Kidney transplantation‡ Stomach Mucormycosis Rhizopus oryzae Fungus No Yes
16 M/69 Diabetes mellitus Maxillary sinus Mucormycosis Rhizopus oryzae NT Yes Yes
GM, serum galactomannan; M, male; F, female; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; CKD, chronic kidney disease; A. 
fumigatus, Aspergillus fumigatus; A. flavus, Aspergillus flavus; A. tamarii, Aspergillus tamarii; A. oryze, Aspergillus oryze; NG, no growth; NT, not tested (insuffi-
cient samples remaining); Neg, negative; Pos, positive.
*Liver transplantation due to hepatocellular carcinoma, †Lung transplantation due to idiopathic pulmonary fibrosis, ‡Kidney transplantation due to diabetic ne-
phropathy, §Biopsies of chest wall soft tissue and left rib.
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in FFPE specimens. 
In all 31 FFPE samples that produced amplifiable DNA re-
sults, fungi were identified to the genus or species level. In two 
cases with a histopathologic diagnosis of aspergillosis, Mucora-
les-specific DNA was identified by sequencing PCR products. 
Although this may have been due to tissue specimen contami-
nation, the risk of misdiagnosis by histopathology cannot be 
excluded. Similar cases have been described in cases con-
firmed by culture.19 
Two samples with a histopathologic diagnosis of aspergillo-
sis were identified as Mucorales: L. ramosa and R. oryzae. The 
Lichtheimia species (formerly known as Absidia) are currently 
regarded as emerging pathogens among Mucoralean fungi.20 
In the present study, the male patient identified with L. ramosa 
infection had a history of hepatocellular carcinoma and had 
undergone liver transplantation prior to infection. In addition, 
he was under immunosuppressive medication. Biopsy from a 
buttock revealed mucormycosis by PCR product sequencing. 
Although it is generally known to have low virulence, cases of 
mucormycosis due to L. ramosa in immunocompromised 
hosts have been reported.20,21 Chaumont, et al.22 reported a 
case of cutaneous mucormycosis requiring aggressive surgical 
debridement. 
The second case, initially diagnosed by histopathology as 
aspergillosis, was found to be due to R. oryzae by PCR. This 
patient had a history of aplastic anemia before fungal infec-
tion and displayed rapid clinical deterioration resulting in 
death. R. oryzae is the most common cause of zygomycosis 
and is a life-threatening infection that usually occurs in pa-
tients with diabetic ketoacidosis.23 
Four samples histopathologically diagnosed as aspergillosis 
produced ambiguous results. In addition to PCR results corre-
sponding as Aspergillus species, three samples with a concom-
itant uncultured fungus was identified, and in the other sam-
ple, N. oryzae strain was identified. Because fungal ribosomal 
genes have many similarities, identification at the species level 
can only be performed by sequencing PCR products.24 Howev-
er, it has been shown that even targets of base pairs of less than 
300 bp within 18S rDNA may not be sufficient to differentiate 
genera.25 Furthermore, A. fumigatus cannot be identified at the 
species level by PCR targeting 18S rDNA, because target se-
quences show high analogy to several Ascomycota.25 We be-
lieve this lack of specificity may have explained the uncultured 
fungus clones identified in the present study.
Since aspergillosis and mucormycosis respond to different 
antifungal agents, delayed diagnosis or treatment might lead to 
devastating results.26 Mucormycosis is an aggressive and inva-
sive disease, and early surgical debridement of involved tissues 
and initiation of proper antifungal agents are crucial.27 Our 
study results demonstrate that PCR can be used to differentiate 
and identify fungal species, and thus, provide guidance regard-
ing appropriate antifungal treatment strategies.
Mutations in the cyp51A gene have been documented in 
clinical isolates of patients with a long history of exposure to 
azoles.28,29 The most frequent resistance allele is TR34 in com-
bination with L98H substitution (TR34/L98H).8 Azole-resis-
tant mutations harboring tandem repeats of various sizes in 
the promoter region of the cyp51A gene and point mutations 
leading to amino acid changes in the cyp51A gene have also 
been documented in azole-naive patients.30,31 TR34/L98H and 
TR46/Y121F/T289A are commonly associated with azole-re-
sistance linked to environmental use of azoles in agriculture 
and are often found in azole-naïve patients.32,33 In the present 
study, azole resistance was not detected in three cases (pa-
tients 4, 5, and 9) with a history of prior azole use. Thus, be-
cause sample numbers were small, we suggest larger scale 
studies be performed to investigate azole resistance in pa-
tients with a history of azole exposure.
Several limitations of the present study warrant mention. 
First, the amount of fungal DNA available is crucial when inves-
tigating clinical samples, and DNA degradation and the effects 
of formaldehyde may have reduced DNA amounts in samples. 
Specimens that were collected more than a decade before had 
undergone severe degradation and were lacking viable fungal 
DNA for analysis. Second, culture results or azole susceptibility 
profiles were not considered. Third, as the TR46 and M220 mu-
tations have never been reported in South Korea, a positive 
control for isolates harboring these mutations could not be ac-
quired. Finally, there are many mutations within cyp51A that 
can confer elevated minimum inhibitory concentrations/resis-
tance to triazoles, not just the ones stated in this paper, and 
thus, there may be unknown methods of elevated minimum 
inhibitory concentrations to the triazoles not linked to cyp51A 
mutations that would not be detected by this assay.
Panfungal PCR assay with FFPE samples may provide addi-
tional information of use in fungal species identification. No 
azole-resistance mediating mutations in the A. fumigatus cy-
p51A gene were identified among FFPE samples during study 
period. 
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